Posts Tagged ‘liraglutide’

New Data Shifting Attitudes on Obesity Treatment

July 2, 2015 — The response to new data on obesity treatment — published today in the New England Journal of Medicine — gives us some flicker of hope that attitudes about obesity treatment are shifting. The publication is the 56-week pivotal safety and efficacy study of liraglutide for treating obesity. Xavier Pi-Sunyer and colleagues found that most (63%) […]

Taking a Longer View in Obesity

May 25, 2015 — On Friday, when most people had gone for the Memorial Day weekend, came this headline from a press release: Treatment with Saxenda® for Three Years Reduced the Risk of Developing Type 2 Diabetes Compared with Placebo Ordinarily, releasing information in this way would done to bury bad news that you had to get behind you. In this […]

Diabetes Spawning More Options for Obesity Care

May 21, 2015 — People living with obesity are finally beginning to see more options for obesity care and, in part, they can thank competition to innovate in diabetes care for some of this progress. A particularly visible example of this is liraglutide, which has been available for treating type 2 diabetes since 2009. After six years of use […]

Final Approval for Saxenda in Europe

March 24, 2015 — The European Commission granted final approval late yesterday for Novo Nordisk’s Saxenda brand of liraglutide 3mg to treat obesity. Saxenda is the first obesity treatment in nearly a decade to receive approval in Europe. Novo Nordisk is already in the final stages of preparing to launch Saxenda in the U.S., where it was approved late last […]

Dangerous Crosscurrents for Obesity Medicines

March 12, 2015 — Dangerous crosscurrents remain in the regulatory environment for obesity medicines, even though progress has been considerable over the last five years. You need look no further than headlines of the last week. In just one news cycle Orexigen — the originators of Contrave — made both good and bad news for themselves when they disclosed […]

Europe Opens the Way for Two New Obesity Drugs

January 24, 2015 — Let’s just say it. European regulators were spooked by obesity drugs for quite a few years. So news that first buproprion/naltrexone (Contrave U.S./Mysimba EU) and now liraglutide (Saxenda) have been recommended for approval in Europe is good news indeed. What spooked the Europeans was the experience with rimonobant. The European  Commission (EC) granted Sanofi approval for this obesity treatment in 2006, […]

A Gift on Christmas Eve — Liraglutide Approved for Obesity

December 24, 2014 — We knew it was coming, we just didn’t know when. And then, just as everyone was off to focus on the holiday, came the announcement from FDA — liraglutide approved for obesity. One might think of this as a tardy approval or an early Christmas gift. FDA had been due to approve it by October […]

New Growth in Obesity Treatment Options

November 5, 2014 — Signs of new growth in obesity treatment options are appearing at ObesityWeek 2014 in Boston this week. Novo Nordisk presented a sweeping scope of results on Tuesday from clinical trials with its drug, liraglutide, which is awaiting final approval from FDA. Researchers are presenting new data for other obesity treatments — lorcaserin, bupropion/naltrexone, and phenteramine/topiramate — that […]

A False Choice: Drugs vs Surgery for Obesity

September 23, 2014 — A new study in Acta Diabetologica offers up a comparison of drugs vs surgery for obesity, glycemic control, and cardiovascular risk. It grabbed our attention because liraglutide was the reference drug for the comparison, and that drug has just been recommended for approval in obesity treatment by an expert FDA committee. But the study leaves us […]

FDA Expert Panel Says Yes to Liraglutide for Obesity

September 11, 2014 — Yes is the word from an FDA expert panel that today considered liraglutide 3mg for treating obesity. The Endocrinologic and Metabolic Drugs Advisory Committee voted 14-1 that the risk/benefit profile was favorable. Efficacy data for liraglutide was not really up for much debate. FDA statistician Bradley McEvoy raised a methodological issue with the way that […]